Remission and Survival Following Monthly Intraarterial Cisplatinum in Nonresectable Hepatoma

REFERENCES

• Kew M.C. Hepatic Tumors and Cysts. Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathology/Diagnosis/Management, M. Feldman, M.H. Sleisenger, B.F. Scharschimdt. 6th Ed, W.B. Saunders, Philadelphia 1998; Vol. 1: 1364–1387
   Google Scholar
• Godley P.A., Sandler R.S. Liver Cancer. Digestive Diseases in the United States: Epidemiology and Impact, J.E. Everhart. Government Printing Office, Washington, DC 1994; 227–241, NIH publication No. 94-1447
   Google Scholar
• El-Serag H.B., Mason A.C. Rising Incidence of Hepatocellular Carcinoma in the United States. N. Engl. J. Med. 1999; 340: 745–750
   PubMed Web of Science ®Google Scholar
• McDermott W.V., Cady B., Georgi B., Steele G., Khettry U. Primary Cancer of the Liver. Evaluation, Treatment and Prognosis. Arch. Surg. 1989; 124: 552–554
   PubMed Web of Science ®Google Scholar
• Johnson P.J. Why Can't We Cure Primary Liver Cancer ?. Eur. J. Cancer 1995; 31A: 1562–1564
   PubMed Web of Science ®Google Scholar
• Huguet C., Stipa F., Gavelli A. Primary Hepatocellular Cancer: Western Experience. Surgery of the Liver and Biliary Tract, L.H. Blumgart. Livingstone, Edinburgh 1994; Vol. 2: 1365–1369, Chap. 92
   Google Scholar
• Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., Montalto F., Ammatuna M., Morabito A., Gennari L. Liver Transplantation for the Treatment of Small Hepatocellular Carcinoma in Patients with Cirrhosis. N. Engl. J. Med. 1996; 334(1)693–699
   PubMedGoogle Scholar
• Regalia E., Fassati L.R., Valente U., Pulvirenti A., Damilano I., Dardano G., Montalto F., Coppa J., Mazzaferro V. Pattern and Management of Recurrent Hepatobiliary Carcinoma After Liver Transplantation. J. Hepatobiliary Pancreat. Surg. 1998; 5(1)29–34
   PubMedGoogle Scholar
• Studies on the Chemotherapy with 5-Fluorouracil in Transcatheter Chemoembolization (TAE) Treated Patients with Resectable or Non-resectable Hepatocellular Carcinoma. Cancer Chemother. Pharmacol. 1989; 23: S29–S32
   PubMed Web of Science ®Google Scholar
• Nakamura H., Mitani T., Murakami T., Hashimoto T., Tsuda K., Nakanishi K., Ishida T., Tomodo K., Hori S., Kozuka T., et al. Five Year Survival After Transcatheter Chemoembolization for Hepatocellular Carcinoma. Cancer Chemother. Pharmacol. 1994; 33: S89–S92
   PubMed Web of Science ®Google Scholar
• A Comparison of Lipiodol Chemoembolization and Conservation Treatment for Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 1995; 332: 1256–1261
   PubMed Web of Science ®Google Scholar
• Kasugai H., Kojima J., Tatsuta M., Okuda S., Sasaki Y., Imaoka S., Fujita M., Ishiguro S. Treatment of Hepatocellular Carcinoma by Transcatheter Arterial Embolization Combined with Intraarterial Infusion of a Mixture of Cisplatin and Ethiodized Oil. Gastroenterology 1989; 97(4)965–971
   PubMed Web of Science ®Google Scholar
• Lin D., Liaw Y.F., Lee T.Y., Lai C.M. Hepatic Arterial Embolization in Patients with Unresectable Hepatocellular Carcinoma: A Randomized Controlled Trial. Gastroenterology 1988; 94(2)453–456
   PubMed Web of Science ®Google Scholar
• Venook A.P., Stagg R.J., Lewis B.J., Chase J.L., Ring E.J., Maroney T.P., Hohn D.C. Chemoembolization for Hepatocellular Carcinoma. J. Clin. Oncol. 1990; 8(6)1108–1114
   PubMed Web of Science ®Google Scholar
• Pelletier G., Roche A., Ink O. A Rrandomized Trial of Hepatic Arterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma. J. Hepatol. 1990; 11: 181–184
   PubMed Web of Science ®Google Scholar
• Raoul J.L., Guyader D., Bretagne J.-F., Heautot J.F., Duvauferrier R., Bourguet P., Bekhechi D., Deugnier Y.M., Gosselin M. Prospective Randomized Trial of Chemoembolization Versus Intraarterial Injection of 131I-Labeled-Iodized Oil in the Treatment of Hepatocellular Carcinoma. Hepatology 1997; 26(5)1156–1161
   PubMed Web of Science ®Google Scholar
• Colleoni M., Liessi G., Mastrapasqua G., Nelli P., Vicario G., Sgarbossa G., Pancheri F., Manente P. Intraarterial Chemotherapy Followed by Chemo-embolisation in Unresectable Hepatocellular Carcinoma. Eur. J. Cancer 1997; 33(1)56–60
   PubMed Web of Science ®Google Scholar
• Order S.E., Stillwagon G.B., Klein J.L., Leichner P.K., Siegelman S.S., Fishman E.K., Ettinger D.S., Haulk T., Kopher K., Finney K., et al. Iodine 131 Antiferritin: A New Treatment Modality in Hepatoma: A Radiation Oncology Therapy Group Study. J. Clin. Oncol. 1985; 3(12)1573–1582
   PubMed Web of Science ®Google Scholar
• Stillwagon G.B., Order S.E., Guse C., Leibel S.A., Asbell S.O., Klein J.L., Leichner P.K. Prognostic Factors in Unresectable Hepatocellular Cancer: Radiation Therapy Oncology Group Study 83-01. Int. J. Radiat. Oncol. Biol. Phys. 1991; 20: 65–71
   PubMed Web of Science ®Google Scholar
• Robertson J.M., Lawrence T.S., Dworzanin L.M., Andrews J.C., Walker S., Kessler M.L., Du Ross D.J., Ensminger W.D. Treatment of Primary Hepatobiliary Cancer with Conformal Radiation Therapy and Regional Chemotherapy. J. Clin. Oncol. 1993; 11: 1286–1293
   PubMed Web of Science ®Google Scholar
• Sherman D.M., Weichelsbaum R., Order S.E., Cloud L., Trey C., Piro A.J. Palliation of Hepatic Metastases. Cancer 1978; 41: 2013–2017
   PubMed Web of Science ®Google Scholar
• Ettinger D.S., Leichner P.K., Siegelman S.S., Fishman E.K., Klein J.L., Order S.E. Computed Tomography Assisted Volumetric Analysis of Primary Liver Tumor as a Response to Therapy. Am. J. Clin. Oncol. 1985; 8: 413–418
   PubMed Web of Science ®Google Scholar
• Epstein B.E., Pajak T.F., Haulk T.L., Herpst J.M., Order S.E., Abrams R.A. Metastatic Nonresectable Fibrolamellar Hepatoma. Am. J. Clin. Oncol. 1999; 22(1)22–28
   PubMed Web of Science ®Google Scholar
• Kouroumalis E., Skordilis P., Thermos K., Vasilaki A., Moschandrea J., Manousos O.N. Treatment of Hepatocellular Carcinoma with Octreotide: A Randomised Controlled Study. Gut 1998; 42: 442–447
   PubMed Web of Science ®Google Scholar
• Mannesis E.K., Giannoulis G., Zoumpoulis P., Vafiadou I., Hadziyannis S.J. Treatment of Hepatocellular Carcinoma with Combined Suppression and Inhibition of Sex Hormones: A Randomized, Controlled Trial. Hepatology 1995; 21: 1535–1542
   PubMed Web of Science ®Google Scholar
• Chao Y., Chan W.K., Huang Y.S., Teng H.C., Wang S.S., Lui W.Y., Whang-Peng J., Lee S.D. Phase II Study of Flutamide in the Treatment of Hepatocellular Carcinoma. Cancer 1996; 77: 635–639
   PubMed Web of Science ®Google Scholar
• Tamoxifen in Treatment of Hepatocellular Carcinoma: A Randomised Controlled Trial. Lancet 1998; 352: 17–20
   PubMed Web of Science ®Google Scholar
• Ji S.K., Park N.H., Choi H.M., Kim Y.W., Lee S.H., Lee K.H., Ahn S.Y., Lee S.U., Han B.H., Park B.C. Combined Cisplatinum and alpha Interferon Therapy of Advanced Hepatocellular Carcinoma. Korean J. Intern. Med. 1996; 11(1)58–68
   PubMedGoogle Scholar
• Moore D., Jr, Pazdur R. Systemic Therapies for Unresectable Primary Hepatic Tumors. J. Surg. Oncol. 1993, Suppl. 3: 112–114
   Google Scholar
• Ravry J.R., Omura G.A., Bartolucci A.A. Phase II Evaluation of Doxorubicin Plus Bleomycin in Hepatocellular Carcinoma: A Southeastern Cancer Study Group Trial. Cancer Treat. Rep. 1984; 68: 1517–1518
   PubMedGoogle Scholar
• Melia W.M., Westaby D., Williams R. Diamminodichloride Platinum (Cisplatinum) in the Treatment of Hepatocellular Carcinoma. Clin. Oncol. 1981; 7: 275–280
   PubMed Web of Science ®Google Scholar
• Ravry J.R., Omura G.A., Bartolucci A.A. Phase II Evaluation of Cisplatinum in Advanced Hepatocellular Carcinoma and Cholangiocarcinoma: A Southeastern Cancer Study Group Trial. Cancer Treat. Rep. 1986; 70: 311–312
   PubMedGoogle Scholar
• Falkson G., Ryan L.M., Johnson L.A., Simson I.W., Coetzer B.J., Carbone P.P., Creech R.H., Schutt A.J. A Randomized Phase II Study of Mitoxantrone and Cisplatin in Patients with Hepatocellular Carcinoma: An ECOG Study. Cancer 1987; 60: 2141–2145
   PubMed Web of Science ®Google Scholar
• Bobbio-Pallavicini E., Porta C., Moroni M., Bertulezzi G., Civelli L., Pugliese P., Nastasi G. Epirubicin and Etoposide Combination Chemotherapy to Treat Hepatocellular Carcinoma Patients: A Phase II Study. Eur. J. Cancer 1997; 33(11)1784–1788
   PubMed Web of Science ®Google Scholar
• Blesing C.H., Kerr D.J. Intra-hepatic Arterial Drug Delivery. J. Drug Target 1996; 3(5)341–347
   PubMed Web of Science ®Google Scholar
• Carr B.I. Escalating Cisplatin Doses by Hepatic Artery Infusion (HAI) for Advanced Stage Hepatocellular Carcinoma (HCC). ASCO Proc. 1996, 15: 198
   Google Scholar
• Carr B.I. A Controlled Prospective Randomized Trial Comparing Intraarterial (I/A) Cisplatinum, Doxorubicin and S/Q Interferon Alpha, with or without Lipiodol for Hepatocellular Carcinoma (HCC). Hepatology 1992; 16: 60
   PubMedGoogle Scholar
• Onohara S., Kobayashi H., Itoh Y., Shinohara S. Intraarterial cis-Platinum Infusion with Sodium Thiosulfate Protection and Angiotensin II Induced Hypertension for Treatment of Hepatocellular Carcinoma. Acta Radiol. 1988; 29(2)197–202
   PubMed Web of Science ®Google Scholar
• Kajanti M., Rissanen P., Virkkunen P., Franssila K., Mantyla M. Regional Intraarterial Infusion of Cisplatin in Primary Hepatocellular Carcinoma. Cancer 1986; 58(11)2386–2388
   PubMed Web of Science ®Google Scholar
• Shibata J., Fujiyama S., Sato T., Kishimoto S., Fukushima S., Nakano M. Hepatic Arterial Injection Chemotherapy with Cisplatin Suspended in an Oily Lymphographic Agent for Hepatocellular Carcinoma. Cancer 1989; 64(8)1586–1594
   PubMed Web of Science ®Google Scholar
• Patt Y.Z., Charnsangavej C., Yoffe B., Smith R., Lawrence D., Chuang V., Carrasco H., Roh M., Chase J., Fischer H., et al. Hepatic Arterial Infusion of Floxuridine, Leucovorin, Doxorubicin, and Cisplatin for Hepatocellular Carcinoma: Effects of Hepatitis B and C Viral Infection on Drug Toxicity and Patient Survival. J. Clin. Oncol. 1994; 12(6)1204–1211
   PubMed Web of Science ®Google Scholar
• Mavlight G.M., Patt Y.Z., Haynie T.P., Carrasco C.H., Charnsangevej C., Wallace S. Differential Tumor Regression Inpatients with Bilobar Hepatic Metastases and Dual Arterial Supply: Evidence Supporting the Advantage of Intraarterial Over Intravenous Route of Drug Delivery. Sel. Cancer Ther. 1989; 5(1)37–45
   PubMedGoogle Scholar
• Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., Williams R. Transsection of Esophagus for Bleeding Varices. Br. J. Surg. 1973; 60: 646–649
   PubMed Web of Science ®Google Scholar
• Cancer Staging Manual. 5th Ed., Lippincott-Raven Publishers, New York 1998
   Google Scholar
• Yang N.C., Leichner P.K., Fishman E.K., Siegelman S.S., Frenkel T.L., Wallace J.R., Loudenslager D.M., Hawkins W.G., Order S.E. CT Volumetrics of Primary Cancers. J. Comput. Assisted Tomogr. 1986; 10(4)621–628
   PubMed Web of Science ®Google Scholar
• Pavy J.-J., Denekamp J., Letschert J., Littbrand B., Mornex F., Bernier J., Gonzales-Gonzales D., Horiot J.-C., Bolla M., Bartelink H. Late Effects of Normal Tissues Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 1992; 31((5))1345
   Google Scholar
• Cole W.C., Wolf W. Preparation and Metabolism of a Cisplatin/Serum Protein Complex. Chem. Biol. Interact. 1980; 30: 223–235
   PubMed Web of Science ®Google Scholar
• Anand D., Wolf W. A New, Semi-automated System for the Micro-scale Synthesis of (195mPt)cisplatin Suitable for Clinical Studies. Appl. Radiat. Isot. 1992; 43(6)809–814
   Google Scholar
• Mantel N. Evaluation of Survival Data and Two New Rank Order Statistics Arising in Its Consideration. Cancer Chemother. Rep. 1966; 5: 163–170
   Google Scholar
• Kaplan E.L., Meier P. Nonparametric Estimation from Incomplete Observations. JASA 1958; 53: 457–481
   Web of Science ®Google Scholar
• DiBisceglie A.M., Rustgi V.K., Hoofnagle J.H., Dusheiko G.M., Lotze M.T. NIH Conference: Hepatocellular Cancer. Ann. Int. Med. 1988; 108: 390–401
   PubMedGoogle Scholar
• Friedman M.A. Primary Hepatocellular Cancer: Present Results and Future Prospects. Int. J. Radiat. Oncol. Biol. Phys. 1983; 9: 1841–1850
   PubMed Web of Science ®Google Scholar
• Lee Y.-T.N. Systemic and Regional Treatment of Primary Carcinoma of the Liver. Cancer Treat. Rev. 1977; 4: 195–212
   PubMed Web of Science ®Google Scholar
• Nerenstone S.R., Ihde D.C., Friedman M.A. Clinical Trials in Hepatocellular Carcinoma: Current Status and Future Directions. Cancer Treat Rev. 1988; 15: 1–31
   PubMed Web of Science ®Google Scholar
• Okada S., Okazaki N., Nose H., Shimada Y., Yoshimori M., Aoki K. A Phase 2 Study of Cisplatin in Patients with Hepatocellular Carcinoma. Oncology 1993; 50: 22–26
   PubMed Web of Science ®Google Scholar
• Falkson G., Moertel C.G., Lavin P., Pretorius F.J., Carbone P.P. Chemotherapy Studies in Primary Liver Cancer: A Prospective Randomized Clinical Trial. Cancer 1978; 42: 2149–2157
   PubMed Web of Science ®Google Scholar
• Luporini G., Labianca R., Pancera G. Medical Treatment of Hepatocellular Carcinoma. J. Surg. Oncol. 1993, Suppl. 3: 115–118
   PubMedGoogle Scholar
• Kusano S., Katayama M., Uematsu M., et al. Intraarterial Infusion of Dibutyryl Cyclic Adenosine Monophosphate Plus Mitomycin C for Unresectable Hepatocellular Carcinoma: Long-Term Survival and Response to Tumor Growth Inhibition. Acad. Radiol. 1995; 2(4)286–292
   PubMed Web of Science ®Google Scholar
• Nomura F., Ohnishi K., Tanabe Y. Clinical Features and Prognosis of Hepatocellular Carcinoma with Reference to Serum Alpha-Fetoprotein Levels, Analysis of 606 Patients. Cancer 1989; 64: 1700–1707
   PubMed Web of Science ®Google Scholar
• Patt Y., Yoffe B., Charnsangavej C., Pazdur R., Fischer H., Cleary K., Roh M., Smith R., Noonan C.A., Levin B. Low Serum alpha-Fetoprotein Level in Patients with Hepatocellular Carcinoma as a Predictor of Response to 5-FU and Interferon-Alpha-2b. Cancer 1993; 72(9)2574–2582
   PubMed Web of Science ®Google Scholar